Consequently, targeting Src family kinases can dramatically enhance the therapeutic efficacy of anti-RTK drugs including trastuzumab, cetuximab, erlotinib, and sunitinib, indicating that inhibiting cSrc activity is a rational treatment strategy for cancers (such as GBC) resistant to EGFR-targeted therapy. Here, EGFR is linked to cancer.